ClinicalTrials.gov
ClinicalTrials.gov Menu

BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES (TauBasket)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03658135
Recruitment Status : Recruiting
First Posted : September 5, 2018
Last Update Posted : September 5, 2018
Sponsor:
Information provided by (Responsible Party):
Adam Boxer, University of California, San Francisco

Brief Summary:
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel Cohort Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Intravenously Infused BIIB092 in Patients with Four Different Primary Tauopathy Syndromes

Condition or disease Intervention/treatment Phase
Primary Tauopathies Corticobasal Degeneration Syndrome Frontotemporal Lobar Degeneration With Tau Inclusions MAPT Mutation Carriers, Symptomatic Traumatic Encephalopathy Syndrome Nonfluent Aphasia, Progressive Drug: BIIB092 Other: Placebo Phase 1

Detailed Description:

This is a phase 1b randomized, double-blind, safety, and tolerability clinical trial of an investigational drug, called BIIB092 in patients with four different primary tauopathy syndromes: amyloid PET (-) corticobasal syndrome (CBS), nonfluent variant primary progressive aphasia (nfvPPA), symptomatic patients with autosomal dominant genetic forms of frontotemporal lobar degeneration (FTD) due to the presence of a mutation in the microtubule-associated protein tau gene (sMAPT), and traumatic encephalopathy syndromes (TES). Primary tauopathies are neurodegenerative brain disorders in which tau is the only protein that accumulates at autopsy. While Alzheimer's disease (AD) is the most common tauopathy, it is considered a secondary tauopathy, because tau protein accumulates along with another pathogenic protein, amyloid beta. Primary tauopathies are rare diseases for which there is no treatment or cure. The purpose of the this study is to characterize the safety and tolerability profile of intravenous BIIB092 in four primary tauopathies.

A basket design will be used for a parallel evaluation of BIIB092 in four heterogenous clinicopathological syndromes that share a common molecular target (tau).


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

This is a phase 1b, randomized, double-blind, placebo-controlled, parallel cohort study of the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of BIIB092 in patients with 4 different primary tauopathy syndromes: CBS, nfvPPA, sMAPT, and TES.

A basket trial design will be used for a parallel evaluation of BIIB092 in four heterogeneous clinicopathological syndromes that share a common molecular target (tau). There will be four cohorts of approximately 8 participants each, one for each specific primary tauopathy syndrome listed above (for a total of approximately 32 participants). For each diagnostic cohort, eligible participants will be randomized 3:1 to active or placebo (i.e., 6 participants receiving BIIB092 and 2 participants receiving placebo). All eligible participants will be administered study drug (BIIB092 or placebo) as an 1-hour intravenous (IV) infusion q4w for 20 weeks (for a total of 6 infusions).

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double-blind - only investigational pharmacist is unblinded
Primary Purpose: Treatment
Official Title: A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel Cohort Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Intravenously Infused BIIB092 in Patients With Four Different Primary Tauopathy Syndromes
Estimated Study Start Date : September 12, 2018
Estimated Primary Completion Date : December 31, 2019
Estimated Study Completion Date : April 30, 2020


Arm Intervention/treatment
Experimental: BIIB092
The investigational drug, BIIB092, will be given intravenously, every 4 weeks for 20 weeks
Drug: BIIB092
BIIB092 is an investigational monoclonal antibody directed at tau protein

Placebo Comparator: Placebo
Inactive ingredient
Other: Placebo
Inactive ingredient




Primary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events [ Time Frame: 20 weeks ]
    Assess adverse events during 20 weeks administration BIIB092 or Placebo


Secondary Outcome Measures :
  1. Changes in Pharmacokinetic properties of BIIB092 in Plasma [ Time Frame: 20 weeks ]
    Measure steady-state plasma concentrations of BIIB092 and its metabolites

  2. Changes in Pharmacokinetic properties of BIIB092 in Cerebrospinal Fluid [ Time Frame: 20 weeks ]
    Measure steady-state Cerebrospinal fluid concentrations of BIIB092 and its metabolites

  3. Changes in Pharmacodynamic effects of BIIB092 on Cerebrospinal Fluid [ Time Frame: 20 weeks ]
    Measure CSF concentrations of free extracellular tau (eTau)


Other Outcome Measures:
  1. Change in whole brain volume on brain MRI [ Time Frame: 20 weeks ]
    Measure of global volume of interest (whole brain)

  2. Change in regional brain volume on brain MRI [ Time Frame: 20 weeks ]
    Measure of regional volumes of interest (such as ventricles, hippocampus)

  3. Change in functional connectivity on brain MRI [ Time Frame: 20 weeks ]
    Connectivity between brain regions measured using arterial spin labeling (ASL)

  4. Change in functional connectivity on brain MRI [ Time Frame: 20 weeks ]
    Connectivity between brain regions measured using resting state functional MRI (rsfMRI)

  5. Change in functional connectivity on brain MRI [ Time Frame: 20 weeks ]
    Connectivity between brain regions measured using diffusion tensor MRI (DTI)

  6. Change in Cerebrospinal Fluid Biomarkers of phosphorylated tau [ Time Frame: 20 weeks ]
    Measure CSF concentrations of phosphorylated tau protein (p-tau) pg/mL

  7. Change in Cerebrospinal Fluid Biomarkers of neurofilament light chain [ Time Frame: 20 weeks ]
    Measure CSF concentrations of neurofilament light chain protein (NfL) pg/mL

  8. Change in Cerebrospinal Fluid Biomarkers of total tau [ Time Frame: 20 weeks ]
    Measure CSF concentrations of total tau protein (t-tau) pg/mL

  9. Change in Schwab and England Activities of Daily Living (SEADL) scale [ Time Frame: 20 weeks ]
    The SEADL assesses the subject's ability to perform daily activities as reported by the subject, caregiver, and clinician. Rated in 10% increments, with 100% = completely independent to 0% = bedridden and vegetative functions.

  10. Changes in Functional Activities Questionnaire (FAQ) [ Time Frame: 20 weeks ]
    The FAQ measures the subject's ability to perform common activities independently as reported by informant (such as paying bills, preparing a meal, keeping track of current events). Normal = 0 and dependent on others = 3; Sum scores (range 0-30, with higher score impaired function and possible cognitive impairment)

  11. Change in Montreal Cognitive Assessment (MoCA) [ Time Frame: 20 weeks ]
    The MoCA is a brief 30-question test assessing cognitive abilities (such as orientation, short-term memory, executive function/visuospatial ability). Scores range from zero to 30, with a higher score generally considered normal; lower scores indicate possible cognitive impairment.

  12. Change in Neuropsychiatric Inventory-Questionnaire (NPI-Q) [ Time Frame: 20 weeks ]
    The NPI-Q is a brief assessment of neuropsychiatric symptoms (such as delusions, hallucinations). Each symptom is rated (by informant/caregiver) for Severity on a 3-point scale (mild, moderate, severe) and Distress on a 5-point scale (0 to 5). The higher the total Severity and Distress scores the more impactful the symptoms.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   35 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The inclusion criteria are listed below and are the same for each diagnostic cohort, except where noted. Participants must meet all of the specified inclusion criteria to be randomized to study drug (active or placebo) treatment.

    1. Between 35 and 80 years of age (inclusive);
    2. Able to walk at least 10 steps with minimal assistance (stabilization of one arm or use of cane/walker);
    3. MRI at Screening is consistent with the underlying neurodegenerative disease of the respective diagnostic cohort (i.e., CBS, nfvPPA, sMAPT, or TES), with no large strokes or severe white matter disease;
    4. Mini Mental State Exam (MMSE) at Screening is between 20 and 30 (inclusive);
    5. Amyloid beta (Aβ) positron emission tomography (PET) scan (florbetapir or equivalent) at Screening is not consistent with underlying Alzheimer's disease (AD).

      Previous Aβ PET scan negativity (assessed by a certified neuro radiologist) or previous AD CSF biomarker (Aβ)/tau level) negativity may be used instead of performing an Aβ PET scan at Screening at the PI's discretion;

    6. The following medications are allowed, but must be stable for 2 months prior to

      Screening:

      1. FDA-approved AD medications
      2. FDA-approved Parkinson's disease medications;
    7. Other medications (except those listed under exclusion criteria) are allowed as long as the dose is stable for 30 days prior to Screening;
    8. Has a reliable study partner who agrees to accompany the participant to visits, and spends at least 5 hours per week with the participant;
    9. Agrees to 3 lumbar punctures;
    10. Signed and dated written informed consent obtained from the participant and the participant's study partner in accordance with local IRB regulations;
    11. Women of childbearing potential (WCBP) must agree to abstain from sex or use an adequate method of contraception for the duration of the Screening period, the study drug treatment period, and for 155 days after the last dose of study drug;
    12. Males must agree to abstain from sex with WCBP or use an adequate method of contraception for the duration of the study drug treatment period and for 215 days after the last dose of study drug.

      For CBS Only

    13. Meets 2013 consensus criteria for possible or probable corticobasal degeneration (CBD), CBS subtype (Armstrong et al. 2013).

      For nfvPPA Only

    14. Meets 2011 consensus criteria for nfvPPA (Gorno-Tempini et al. 2011). Patients meeting 2013 Armstrong criteria for CBS-nfvPPA or 2017 Movement Disorder Society (MDS) criteria for progressive supranuclear palsy and speech/language disorders (PSP-SL) (Höglinger et al. 2017) would be assigned to this cohort since both of these definitions were derived from the 2011 Gorno-Tempini criteria.

      For sMAPT Only

    15. Has known frontotemporal lobar degeneration- (FTLD-) causative MAPT mutation confirmed in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory (Ghetti et al. 2015);
    16. CDR-FTLD (Knopman et al. 2008) sum of boxes score ≥ 1.0. Sum of boxes is used instead of the global Clinical Dementia Rating Scale (CDR) because the global CDR does not take into account FTLD specific measures;
    17. Has any clinical phenotype of sMAPT.

      For TES Only

    18. Meets 2016 criteria for probable TES (Reams et al. 2016);
    19. At least 5 years or greater between symptom onset and 1st known traumatic brain injury/concussive episode.

Exclusion Criteria:

The exclusion criteria are listed below and are the same for each diagnostic cohort. Participants meeting any of the following exclusion criteria will be excluded from randomization to study drug (active or placebo) treatment.

  1. A diagnosis of probable AD (McKhann et al. 2011) or progressive supranuclear palsy- Richardson's syndrome (PSP-RS) (Höglinger et al. 2017). Since variants of progressive supranuclear palsy (PSP) are known to cause nfvPPA and CBS, a diagnosis of PSP-SL or progressive supranuclear palsy-corticobasal syndrome (PSP- CBS) would not be exclusionary;
  2. Any other medical condition other than CBS, nfvPPA, sMAPT or TES that could account for cognitive or motor deficits (e.g., active seizure disorder, stroke, vascular dementia, substance abuse or alcoholism);
  3. History of a prominent and sustained response to levodopa therapy in the opinion of the PI;
  4. History of significant cardiovascular, hematologic, renal, or hepatic disease (or laboratory evidence thereof);
  5. History of major psychiatric illness or untreated depression that in the opinion of the PI would pose a safety risk or interfere with the appropriate interpretation of study data;
  6. Neutrophil count <1,500/mm3, platelets <100,000/mm3, serum creatinine >1.5 x upper limit of normal (ULN), total bilirubin >1.5 x ULN, alanine aminotransferase (ALT) >3 x ULN, aspartate aminotransferase (AST) >3 x ULN, or International Normalized Ratio (INR) >1.2 at Screening evaluations;
  7. Evidence of any clinically significant findings on Screening or baseline evaluations which, in the opinion of the PI would pose a safety risk or interfere with appropriate interpretation of study data;
  8. Current or recent history (within four weeks prior to Screening) of a clinically significant bacterial, fungal, or mycobacterial infection;
  9. Current clinically significant viral infection;
  10. Major surgery within four weeks prior to Screening;
  11. Any contraindication for MRI or unable to tolerate MRI scan at Screening;
  12. Any contraindication to or unable to tolerate lumbar puncture at Screening, including use of anti-coagulant medications such as warfarin. Daily administration of 81 mg aspirin will be allowed as long as the dose is stable for 30 days prior to Screening;
  13. Participants who, in the opinion of the PI, are unable or unlikely to comply with the dosing schedule or study evaluations;
  14. Prior treatment with BIIB092;
  15. Treatment with another investigational drug within 30 days or 5 half-lives of drug before Screening, whichever is longer. Treatment with investigational drugs other than BIIB092 while on study will not be allowed;
  16. Treatment with systemic corticosteroids within 30 days or 5 half-lives of drug before Screening, whichever is longer. Treatment with systemic corticosteroids while on study will not be allowed;
  17. Known hypersensitivity to the inactive ingredients in the study drug (BIIB092 or placebo);
  18. Known to be pregnant or lactating; or positive pregnancy test at Screening or Baseline (Day 1);
  19. Cancer within 5 years of Screening, except for basal cell carcinoma;
  20. History of serum or plasma progranulin level less than one standard deviation below the normal participant mean for the laboratory performing the assay;
  21. History or evidence at Screening of known disease-associated mutations in GRN, TBK1, C9ORF72, TARBP, CHMPB2, or VCP genes (FTLD causative gene mutations not associated with underlying tau pathology).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03658135


Contacts
Contact: Mary Koestler, RN, PhD 415-476-0661 mary.koestler@ucsf.edu
Contact: Lauren Fisher, B.A. 415-514-5745 lauren.fisher@ucsf.edu

Locations
United States, California
UCSF Memory and Aging Center Recruiting
San Francisco, California, United States, 94158
Contact: Mary Koestler, RN, PhD    415-476-0661    mary.koestler@ucsf.edu   
Contact: Lauren Fisher, BA    415-514-5745    lauren.fisher@ucsf.edu   
Principal Investigator: Adam Boxer, MD, PhD         
Sponsors and Collaborators
University of California, San Francisco
Investigators
Principal Investigator: Adam Boxer, MD, PhD UCSF Memory and Aging Center

Responsible Party: Adam Boxer, Adam Boxer, MD, PhD, Professor of Neurology, University of California, San Francisco
ClinicalTrials.gov Identifier: NCT03658135     History of Changes
Other Study ID Numbers: UCSF-001-AET-1
First Posted: September 5, 2018    Key Record Dates
Last Update Posted: September 5, 2018
Last Verified: August 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Adam Boxer, University of California, San Francisco:
CBS, CBD, nfvPPA, FTD, sMAPT, TES

Additional relevant MeSH terms:
Syndrome
Brain Diseases
Aphasia
Tauopathies
Frontotemporal Lobar Degeneration
Brain Injuries, Traumatic
Dementia
Aphasia, Broca
Primary Progressive Nonfluent Aphasia
Aphasia, Primary Progressive
Pick Disease of the Brain
Frontotemporal Dementia
Disease
Pathologic Processes
Central Nervous System Diseases
Nervous System Diseases
Speech Disorders
Language Disorders
Communication Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Signs and Symptoms
Neurodegenerative Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases
Neurocognitive Disorders
Mental Disorders
Brain Injuries
Craniocerebral Trauma